Recent advances in antibody engineering have been driven by new antibody generation technologies and increasingly sophisticated antibody and antibody-based formats, such as bispecifics and multi-specific antibodies. Able to simultaneously co-engage with different antigen targets, these new antibody formats are currently being broadly adopted by the biopharmaceutical industry, primarily for developing the next-generation of oncology and immune system therapies.
Each of these engineered candidate molecules needs to be expressed and evaluated, which poses serious data management and analysis challenges. Genedata Biologics® systematically designs, clones, and tests large numbers of novel next-generation antibody formats, such as bi- and multi-specifics, knobs-into-holes (KinH), Fab-scFv, IgG-scFv, DVD-Ig, tandem-scFv-Fc and their parametric variants (e.g., linkers, V-domain order, Fc). The system also automates downstream expression, purification, and characterization processes, which substantially increases throughput.
Genedata Biologics resolves major bottlenecks in high-throughput molecular biology and cloning processes. These processes are required to systematically generate and validate DNA constructs to express the desired next-generation molecules. The platform supports multi-specific engineering strategies by identifying the most successful combination of antigen binders and formats and scales up cloning and production by directly integrating with laboratory automation equipment. By automatically aggregating all assay and analytics results, Genedata Biologics also facilitates decision-making to choose the best candidate to move forward.